BARCELONA, Spain, March 3, 2026 /PRNewswire/ — At MWC Barcelona 2026, Enterprise Strategy Group, now part of Omdia, released a technical validation report on Huawei’s New-Gen OceanStor Dorado Converged All-Flash Storage.

The report emphasizes that enterprise data volumes are growing rapidly in the AI era, reshaping how organizations operate and raising the bar for storage infrastructure in terms of performance, resilience, intelligence, and cost-effectiveness. While many storage vendors offer all-flash solutions, architectural design trade-offs often make it difficult to balance performance, reliability, and cost, ultimately limiting the benefits delivered to organizations.

The report provides a comprehensive evaluation of New-Gen OceanStor Dorado Converged All-Flash Storage across performance, resilience, intelligent management, and total cost of ownership (TCO). The results confirm that the product leads the way in these key areas and demonstrates strong market competitiveness, delivering a compelling combination of high performance, strong resilience, and optimal TCO. This meets enterprise needs for digital and intelligent transformation.

Testing conducted in a simulated high-concurrency database environment shows that the all-flash system sustains ultra-high performance of more than 876,256 IOPS, with an average response time of just 32 μs. The system stores diverse data with native and parallel architecture for blocks, files, and objects.

The active-active solution supports seamless failover across data centers. The SmartMatrix full-mesh architecture can tolerate the failure of up to seven out of eight controller enclosures without service interruptions. FlashEver enables cross-gen convergence and eliminates service interruptions during storage replacement. The system delivers end-to-end intelligent protection with built-in ransomware detection for both SAN and NAS.

The DataMaster agent of the iMaster DME data management platform enables automatic system health assessment, performance trend prediction, and fault location within minutes.

In addition, the five-year TCO analysis indicates that New-Gen OceanStor Dorado Converged All-Flash Storage can reduce TCO by up to 64% compared with traditional hybrid storage. This achieves significant savings in procurement, O&M, and energy consumption.

Yuan Yuan, President of Huawei Data Storage Product Line, stated, “This Enterprise Strategy Group technical validation demonstrates Huawei’s ongoing leadership in storage technology innovation. Going forward, we will continue to deepen our innovation efforts and help accelerate the digital and intelligent transformation across industries.”

For more information, visit: https://omdia.tech.informa.com/commissioned-research/articles/huawei-new-gen-oceanstor-dorado-converged-all-flash-storage 

About Enterprise Strategy Group

Enterprise Strategy Group, now part of Omdia, provides focused and actionable market intelligence, demand-side research, analyst advisory services, GTM strategy guidance, solution validations, and custom content supporting enterprise technology buying and selling.

BARCELONA, Spain, March 3, 2026 /PRNewswire/ — At MWC Barcelona 2026, Huawei launched the Xinghe Intelligent Traffic-Encryption Integration Solution, which integrates network intelligence and quantum security. This innovative solution tackles two challenges—mitigating quantum security threats and slashing enterprise network construction costs—in order to help industries worldwide accelerate their transition to become quantum-secure.

In his speech, Fernando Lopez Montes, IP CTO at Huawei’s Spain Enterprise Business Dept, emphasized that the accelerated commercialization of quantum computing and escalated cybersecurity threats were driving the transformation of communication networks toward greater intelligence, efficiency, and intrinsic security. He highlighted the Xinghe Intelligent Network Traffic-Encryption Integration Solution, saying that it offers a feasible, cost-effective, and highly secure next-generation network foundation for various industries.

Cyber security faces mounting threats. Quantum computers are set for commercial rollout three years ahead of schedule, and the rise of quantum “harvest now, decrypt later” attacks is sharply increasing critical risks for industries such as finance. Meanwhile, conventional external Quantum Key Distribution (QKD) solutions require standalone devices and huge investments, with device expenses and optical fiber installations consuming over 60% of the total investment cost—a major barrier to the widespread adoption of quantum encryption networks.

Huawei tackles these obstacles with the Xinghe Intelligent Traffic-Encryption Integration Solution, delivering two technological breakthroughs.

Breakthrough 1: Industry’s first built-in QKD board to integrate the quantum security network and communication network

This board can be directly inserted into a NetEngine 8000E series router, eliminating the need to deploy standalone quantum encryption devices. It revolutionizes network infrastructure by weaving advanced quantum security directly into existing systems, simplifying architecture while accelerating implementation timelines.

Breakthrough 2: Unique high-precision noise reduction algorithm to integrate quantum, negotiation, and communication channels into one

With this cutting-edge algorithm, all three types of signals now seamlessly travel through a single fiber, eliminating the need for additional devices or optical fibers and slashing the overall investment cost by over 60%.

The Xinghe Intelligent Traffic-Encryption Integration Solution seamlessly integrates network intelligence and intrinsic quantum security, dramatically reducing barriers to implementing quantum encryption while driving robust security enhancements.

Huawei is committed to pioneering advancements in network intelligence and quantum security, as well as collaborating with global partners to create intelligent, secure, and efficient next-generation intelligent WANs. Together, we aim to establish a quantum-secure foundation that empowers the digital world.

BARCELONA, Spain, March 3, 2026 /PRNewswire/ — At MWC Barcelona 2026, Li Peng, Huawei’s Senior Vice President and President of ICT Sales & Service, delivered a keynote on how carriers can maximize the value of 5G-A and AI to accelerate towards the agentic Internet era. Li proposed that, as networks converge with AI, carriers have the opportunity to redefine the value of connectivity by upgrading to “5G-A x AI”. This will allow them to not only monetize traffic and experience, but also AI services.

Leap in industry value: Entering a 10-trillion-dollar agentic Internet era

Over the past few years, the mobile industry has steadily evolved from 4G to 5G, and some carriers have begun deploying 5G-A. As networks are stronger than ever, they are bringing intelligent applications to all kinds of devices.

Li said, “This year, we’re entering the agentic Internet era. Networks will not only connect people. They will also connect hundreds of billions of agents.” The rise of agent applications over the next decade, however, will increase connectivity demands, as networks will not simply facilitate human communication but also communication between agents. This will drive carriers to shift from offering traffic to offering high-value services and open up a new market worth of ten trillion dollars.

Business model upgrade: Elevating brands and offerings to unlock new revenue streams

The evolution of network capabilities will also result in changes to carrier business models. In the seven years since the commercialization of 5G, more than 300 carriers around the world have launched new packages to monetize traffic, and this has helped them grow both their revenue and userbase.

As 5G networks continue to mature, experience monetization will be more essential to carriers’ success. 5G SA and 5G-A provide more diverse network resources that more than 30 leading carriers have used to launch experience-based packages to monetize speeds, latency, and more.

By dynamically scheduling resources, carriers can go beyond “best-effort” service to deterministic experience. This helps them strengthen brand reputation and users’ willingness to spend on premium services. By offering services like custom logo displays and multi-level speed boosts, carriers are able to guarantee network performance at critical moments and enhance users’ perception of network quality.

Connectivity and AI service convergence: Unleashing new growth potential with AI-powered consumer, home, and enterprise services

Li also explained how carriers will be able to transform their main services and improve consumer satisfaction by applying AI models.

• AI for consumers: First, AI can be integrated into traditional calling services. There are currently 5.4 billion calling service users around the world, and AI can be used to unlock features like transcription, translation, and AI assistants. Many of these features have already entered large-scale commercial use in China and South Korea. In addition, more and more carriers are launching AI phones to act as portals for the agentic era. They are using these phones to upgrade their B2C services—the largest source of revenue for most carriers.
• AI for homes: In addition to the recent initiatives by carriers to upgrade home broadband towards ultra-gigabit, AI is also being implemented to enable smart home services. For example, acceleration assistants can guarantee deterministic speeds for key services like gaming and livestreaming. Network assistants can help people optimize their Wi-Fi, and resolve network faults via voice commands. AI lifestyle assistants are also a promising avenue for carriers looking to unlock new value from traditional services. By integrating AI with video and storage services, they do things like automatically generating cloud-based family albums that can be shared between devices.
• AI for business: In industrial scenarios, the convergence of 5G-A and AI can be used to transform core workflows and significantly improve production efficiency. For example, in flexible manufacturing, AI-enabled factories will be able to respond to demand in seconds, schedule new production runs in minutes, and deliver new products in hours.

New vision: Helping carriers upgrade their portfolio with AI services

“Looking ahead, there are still many opportunities just waiting to be unlocked with 5G-A and AI. And carriers are in the best position to explore future applications like massive IoT and embodied AI,” said Li. He also recommended three courses of action for carriers to seize these opportunities. First, carriers should evolve all services, devices, and frequency bands to 5G-A to create a thriving network ecosystem. Second, carriers should introduce AI into B.O.M. (business, operations, management) domains. This will provide a foundation for diversified O&M services. Third, carriers should bring intelligence to infrastructure to support the evolution of future network architecture.

“Huawei is ready to work closely with carriers to make the most of 5G-A and AI and help them evolve into AI service providers,” concluded Li. “We can work with carriers to upgrade their main services through the multi-agent collaboration platform. We can also help them build AI-centric networks for more efficient operations. Together, we can unlock a world of new opportunities, and lay a strong foundation for future networks.”

MWC Barcelona 2026 will be held from March 2 to March 5 in Barcelona, Spain. During the event, Huawei will showcase its latest products and solutions at stand 1H50 in Fira Gran Via Hall 1.

The era of agentic networks is now approaching fast, and the commercial adoption of 5G-A at scale is gaining speed. Huawei is actively working with carriers and partners around the world to unleash the full potential of 5G-A and pave the way for the evolution to 6G. We are also creating AI-Centric Network solutions to enable intelligent services, networks, and network elements (NEs), speeding up the large-scale deployment of level-4 autonomous networks (AN L4), and using AI to upgrade our core business. Together with other industry players, we will create leading value-driven networks and AI computing backbones for a fully intelligent future.

For more information, please visit: https://carrier.huawei.com/en/minisite/events/mwc2026/ 

LONDON, March 2, 2026 /PRNewswire/ — The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger. Hailing from rock and roll roots, Georgia May and Lizzy have unique individual styles and personalities, reflected in their unique choice of scents. English Pear & Freesia and English Pear & Sweet Pea offer two takes on the perfect pear, both featuring this timeless, quintessential Jo Malone London ingredient.

The British fragrance and lifestyle house celebrates English Pear & Freesia and English Pear & Sweet Pea with British models Georgia May and Lizzy Jagger.

Georgia May

Jagger Georgia May began modelling at a young age, featuring in campaigns for a variety of global beauty and fashion brands. She launched her own skincare brand MAY Botanicals in 2023. She co-owns hair dye brand Bleach London and is the Wellbeing Ambassador for the British Beauty Council.

Lizzy Jagger

Lizzy first appeared on the catwalk in 1998 and has been modelling ever since, representing many designers at fashion weeks and featuring in campaigns for global brands. She is an advocate for women’s rights and worked on the award-winning documentary Equal Means Equal with Kamala Lopez, pushing for Women’s Equality Day to become Women’s Equality Week.

The campaign

Experience the sunlit orchard. Sister scents, one bond and an English pear in every bottle.

English Pear & Freesia: a cult classic

Orchards steeped in golden sunshine, warming the russet curves of luscious pears. The sensuous freshness of the just-ripe fruit wrapped in elegant white freesias, enhanced with rose and rooted in patchouli.

Top: Williams Pear

Heart: Freesia

Base: Patchouli

‘I love it because it’s classic and elegant. I feel I can reach for it every day and wear it anywhere. It’s really timeless’—Georgia May Jagger

English Pear & Sweet Pea: a new classic

Sun-warmed orchards spring to life as tempting green pears fill the branches. The luscious fruits enveloped in softly scented pastel sweet peas, nestled on a base of powdery white musk.

Top: Williams Pear

Heart: Sweet Pea

Base: White Musk

‘I can’t help but smile when I wear English Pear & Sweet Pea. It’s playful, subtle, and instantly makes my day better’—Lizzy Jagger

About Jo Malone London: Since 1994 Jo Malone London has created a palette of exquisitely simple, elegant scents and curated a world where every sense is indulged. Acquired by The Estée Lauder Companies Inc. in 1999, today the brand is internationally known for its unexpected fragrances and distinctly British character. Discover these new products alongside the full collection from March 2026, online and in-store. Follow Jo Malone London on TikTok, Instagram, Facebook, X, YouTube, LinkedIn and Pinterest @JoMaloneLondon #EnglishPear

SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ — US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology laboratory serving integrative and functional medicine practitioners.

The merger marks a significant milestone for the global functional laboratory industry. It brings together the two organizations’ specialized expertise and a shared commitment to clinical relevance, scientific rigor, and practitioner support. The partnership expands both companies’ international footprint while enhancing access to comprehensive, clinically actionable testing for healthcare providers worldwide.

US BioTek Laboratories brings decades of experience in immune reactivity, food sensitivity, and specialty biomarker testing, while NutriPATH Pathology is recognized for its expertise in functional pathology, nutritional assessment, and gut health diagnostics. Together, the organizations will offer an expanded portfolio of testing solutions designed to support personalized, root-cause-focused care.

Jack Frausing, CEO of US BioTek Laboratories, commented,

“This merger marks an exciting new chapter for both US BioTek and NutriPATH. Our shared philosophy centers on providing clinicians with meaningful data they can trust and apply in practice. By bringing our teams and capabilities together, we are strengthening our ability to support practitioners with deeper insights, improved access, and expanded innovation.”

James Cavaggion, CEO of NutriPATH, alongside Directors Mary Cavaggion and Andrew Cavaggion, shared:

“This is more than a combination of two companies — it is a strategic alignment of values, scientific expertise, and a mutual dedication to advancing functional medicine globally.”

NutriPATH Pathology will continue to operate with its established brand presence in Australia, maintaining continuity for practitioners while gaining access to expanded resources, technologies, and collaborative scientific development. Clients of both organizations can expect a seamless transition and ongoing commitment to service excellence.

About US BioTek Laboratories

US BioTek Laboratories is a leading functional laboratory dedicated to delivering advanced immunological and specialty testing to integrative, functional, and personalized healthcare providers. Known for its expertise in food sensitivity testing, immune markers, toxin testing, and clinically actionable reporting, US BioTek partners closely with practitioners to support data-driven, patient-centered care.

About NutriPATH Pathology

NutriPATH Pathology is a trusted functional pathology laboratory based in Australia, providing comprehensive testing solutions across gut health, nutritional status, hormones, and metabolic markers. NutriPATH is widely recognized for its practitioner education, clinical support, and commitment to advancing functional medicine diagnostics.

Logo – https://laotiantimes.com/wp-content/uploads/2026/03/us_biotek_laboratories_and_nutripath_logo.jpg 

Australia’s Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk’s SKY-0515 orally-administered small molecule therapy for the treatment of Huntington’s disease meets TGA eligibility criteria for registration via the provisional approval pathway.

Skyhawk delivered its application for provisional approval to the TGA today.

More than 115 patients are now on trial with SKY-0515.

BOSTON, March 3, 2026 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces that Australia’s Therapeutic Goods Administration (TGA), responsible for the approval of the safety, quality, and efficacy of therapeutic goods, has determined that the Company’s SKY-0515 orally-administered small molecule therapy for the treatment of Huntington’s disease meets TGA eligibility criteria for registration via the provisional approval pathway.

Skyhawk Therapeutics, Inc. ‘Phase 1 Part C patient cohort cUHDRS and its components at 3, 6 and 9 months for patients who received SKY-0515 continuously for 9 months, once a day, with the data at 4mg and 9mg pooled (n=17),’ January 2026. Note: Error bars represent standard error of the mean; Propensity score weighting (n=325) was performed using Enroll-HD and TRACK-HD.

Skyhawk delivered its application submission to the TGA for provisional approval today.

“We are grateful that the TGA has determined SKY-0515 for the treatment of Huntington’s disease meets its eligibility criteria for potential provisional approval,” said Bill Haney, Skyhawk’s CEO. “This represents an important first step toward what could be an accelerated path to approval in Australia and the world, offering the possibility of a disease modifying treatment for Huntington’s patients who urgently need therapies for this devastating disease.”

Treatment with SKY-0515 results in dose-dependent reductions of mHTT and PMS1, key drivers of Huntington’s disease pathology. SKY-0515 has demonstrated excellent central nervous system exposure and been generally safe and well tolerated.

Patients receiving SKY-0515 in the Phase 1C trial of SKY-0515 demonstrate mean Composite Unified Huntington’s Disease Rating Scale (cUHDRS) improvement from baseline. At nine months this improvement is +0.64 points in a pooled analysis, compared to expected worsening at nine months of cUHDRS in symptomatic patients of -0.73 points, based on propensity score weighting using Enroll-HD and TRACK-HD.

Huntington’s disease is a rare, inherited and ultimately fatal neurodegenerative disorder that affects hundreds of thousands of people worldwide, including more than 40,000 symptomatic patients in the United States and over 2,000 Australians.^1,2 There are currently no approved disease-modifying treatments which slow or halt disease progression.²

SKY-0515 is a small molecule RNA splicing modifier developed through Skyhawk’s novel RNA-splicing platform, SKYSTAR^®.

SKY-0515 is the first Skyhawk drug in clinical trials.

Skyhawk is developing additional novel drugs to treat neurological diseases for which there are no approved disease-modifying therapies.

About SKY-0515’s Phase 1 Clinical Study
SKY-0515’s Phase 1 clinical trial is a first-in-human trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKY-0515 in healthy volunteers and individuals with Huntington’s disease (HD). The trial is separated into three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a double-blind placebo-controlled parallel design study of two dose levels of SKY-0515 and placebo in individuals with HD (HD-ISS Stage 1, 2, or mild Stage 3) for 84 days followed by a 12 month extension of active treatment where all participants receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study include evaluating mutant HTT protein and PMS1 mRNA. The first patients were dosed in SKY-0515’s Part C in January 2025. Enrollment in Phase 1C of the SKY-0515 trial is now complete and the trial is ongoing.

About SKY-0515’s Phase 2/3 FALCON-HD Clinical Study
FALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in 120 participants with Stage 2 and early Stage 3 HD across 12 sites in Australia and New Zealand, and 400 participants with Stage 2 and early Stage 3 HD in 40+ worldwide sites. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels or placebo, for a treatment period of at least 12 months. This trial aims to confirm the potential of SKY-0515 to modulate RNA splicing and reduce mHTT and PMS1 proteins, which are implicated in the pathology of Huntington’s disease, and to assess the efficacy of the SKY-0515 in affecting the rate of Huntington’s disease progression. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company which uses its proprietary platform, SKYSTAR^®, to discover and develop small molecule RNA modulating therapies for the world’s most intractable diseases. For more information visit www.skyhawktx.com.

Skyhawk Contact
Maura McCarthy
Head of Corporate Development
maura@skyhawktx.com

References

1. Australian Institute of Health and Welfare (AIHW) 2025, Huntington’s disease in Australia, viewed 8 February 2026, https://www.aihw.gov.au/reports/neurological-conditions/huntingtons-disease-in-australia
2. Huntington’s Disease Society of America (HDSA) 2026, Overview of Huntington’s Disease, viewed 8 February 2026, https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/

Photo – https://laotiantimes.com/wp-content/uploads/2026/03/skyhawk_therapeutics__phase_1_part_c_patient_cohort_cuhdrs.jpg 

ANAHEIM, Calif., March 3, 2026 /PRNewswire/ — At a time when global palates are shifting toward layered, high-contrast flavors, two category leaders are choosing collaboration over competition.

This March at Natural Products Expo West, O’s Bubble and Pink Rocket will officially debut their first joint innovation — a ‘Swicy’ fusion concept that bridges beverage culture and Korean street food tradition.

O’s Bubble, the flagship brand under Orbitel International Group, has transformed bubble tea into a scalable global retail format, building its reputation on texture, comfort, and modern Asian lifestyle appeal.

Pink Rocket, a dynamic brand under Young Poong Co., Ltd., represents Korea’s fiery street-food heritage, engineered with manufacturing precision and global ambition.

Together, the two brands — each backed by their respective parent companies… introduce what they define as “Swicy,” a new flavor language where sweetness and heat coexist intentionally, not accidentally.

“We’ve spent years redefining how bubble tea lives beyond the café. This collaboration with Young Poong allows us to extend that thinking into new formats and flavor territories. Swicy isn’t just a pairing, it’s a flavor language we are defining and owning — a reflection of how modern consumers eat: layered, curious, and culturally fluid. And with topokki, Korea’s iconic comfort food, this partnership goes beyond export—we’re evolving a classic for what’s next.” said Fanny Chen, CEO, Orbitel International Group.

Introducing the Sweet & Spicy Hit
O’s Bubble approaches innovation from a different direction — reengineering bubble tea across frozen, microwaveable, and ready-to-enjoy formats. With deep understanding of North American consumers and strong retail execution, the brand has become an Amazon Best Seller in North America, demonstrating its ability to convert cultural flavor into scalable commercial success.

Orbitel International Group serves as the sole distributor of Young Poong’s Pink Rocket brand in the U.S. market, further strengthening the strategic bridge between the two companies.

Debuting at Expo West, the new co-developed concept blends creamy sweetness with calibrated Korean heat — layered with chew, sauce, and contrast. It draws inspiration from both bubble tea indulgence and Korean street-side spice culture.

The ‘Swicy’ collaboration will be featured at both the O’s Bubble booth and the Young Poong / Pink Rocket booth during Expo West 2026.

About Orbitel International Group
Orbitel International Group is a global food innovation company committed to bringing authentic Asian lifestyle products to the world. Its flagship brand O’s Bubble has redefined bubble tea — from frozen (BOBA 1.0) to microwaveable (BOBA 2.0) to its latest ready-to-eat Boba (BOBA 3.0). Operating in 50+ countries, Orbitel is trusted by retailers, distributors, and foodservice leaders for its supply chain excellence, product innovation, and strategic partnerships — all built on the belief that food and drink should always deliver Our Best Times. Learn more about us at https://orbitelinternational.com

Media Contact:
Ms. Nina Jen
Global Marketing, Orbitel International Group
nina@orbitel.com.tw